All In Biotech

Drug Trial Radar · NCT01218789

Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Open-Label Safety Study of a 1-Year 20 mg Dose Regimen of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder (N24HSWD) in Blind Individuals With No Light Perception

Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

140

Planned (sponsor's estimate)

Start

Oct 28, 2010

Primary completion

Dec 5, 2024

Study completion Dec 5, 2024

Sponsor

Lead sponsor
Vanda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 11, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety of a one year open-label treatment of tasimelteon in male and female subjects with Non-24-Hour Sleep-Wake Disorder.

Conditions

  • Non 24 Hour Sleep Wake Disorder

Interventions

  • tasimelteonDrug

    20 mg tasimelteon capsules, PO daily for 1 year

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EvaluationsTime frame: Week 4
  2. Safety EvaluationsTime frame: Week 8
  3. Safety EvaluationsTime frame: Week 12
  4. Safety EvaluationsTime frame: Week 16
  5. Safety EvaluationsTime frame: Week 26
  6. Safety EvaluationsTime frame: Week 34
  7. Safety EvaluationsTime frame: Week 42
  8. Safety EvaluationsTime frame: Week 52

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Garches, France

  • Site not named

    Lille, France

  • Site not named

    Lyon, France

  • Site not named

    Montpellier, France

  • Site not named

    Paris, France

  • Site not named

    Rennes, France

  • Site not named

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.